UNH UNITEDHEALTH GROUP INC

Price Chart

Executive Summary

Argus Research double-upgraded UnitedHealth Group (UNH) from Hold to Buy on April 22, 2026, setting a $400 price target. The call aligns with a strongly bullish consensus where 76.5% of analysts rate the stock Buy or Strong Buy. Argus's own track record is weak — 50% accuracy on just 2 calls with a -17.1% average return, the worst among covered firms. The mean analyst target sits at $390.35, implying 2.1% upside; the median of $400 matches Argus's target. Price target range spans $287 to $444. Insider activity shows a $284K sale on April 23 by an officer, slightly opposing the upgrade, while congressional buys and a massive $4.4B new stake from Norges Bank provide bullish cross-signals. EPS revisions have been positive over the past 30 days, with 25 upward revisions for the current fiscal year and zero downward. Short interest is elevated at 62.9% of float, suggesting lingering bearish positioning. Bottom line: Argus's upgrade reinforces the predominant bullish view, but its low credibility and the insider sell warrant caution. The call is more confirmatory than catalytic.

Impact Score

Consensus & Targets

Of 34 analysts covering UNH, 26 rate it Buy (7 Strong Buy, 19 Buy), 7 Hold, 0 Sell, and 1 Strong Sell — a 76.5% bullish consensus. The consensus direction is clearly positive, and Argus's upgrade brings it into alignment with the majority.

Current price: $382.48. Analyst price targets: mean $390.35, median $400, high $444, low $287. Implied upside to the mean is 2.1%, to the median 4.6%. Argus's $400 target sits exactly at the median and slightly above the mean, indicating an in-line view with the consensus range.

Recent Analyst Activity

Analyst activity over the past 30 days shows 0 upgrades and 0 downgrades, but the Argus upgrade itself occurs on the trigger date. EPS revisions are positive: 30-day revisions up for the current quarter (16 up, 4 down), current fiscal year (25 up, 0 down), and next year (23 up, 2 down). Revisions are trending higher overall.

Firm Track Record — Argus Research

Argus Research accuracy: 54% on 339 calls | avg return: 3.7%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Argus Research has a 50% accuracy rate on 2 scored calls with an average return of -17.1%, the worst among all firms covering UNH. The best-performing firms are JP Morgan (67% on 6 calls, +6.5% avg return), HSBC (67% on 3 calls, -8% avg return), and Piper Sandler (67% on 6 calls, +4.7% avg return). Argus's small sample size and poor returns reduce the weight of this upgrade.

Earnings Estimates

Next earnings: Jul 27, 2026

Cross-Platform Signals

Insider trading: a single $284K sale by officer Conway Patrick Hugh on April 23 provides a mildly bearish signal opposing the upgrade. Congressional activity: multiple small buys in March and April from Reps. Salazar, Khanna, and McCormick. Institutional flows: Norges Bank initiated a $4.38B new position, Two Sigma more than doubled its stake (+690.9%), and Cullen Capital added 40.7%. Short interest stands at 62.9% — extremely elevated, signaling persistent bearish bets. The institutional buying and short interest create a tug-of-war, with the upgrade leaning bullish.

Documents Analyzed

Report based on filing metadata.

US Market Status